论文部分内容阅读
应用CD3AK细胞／IL－2治疗癌症患者30例，其中CR＋PR14例，有效率为46％。根据Ker－nofsky的生活质量标准分析，治疗后（49．66±8．88）较治疗前（37．88±11．84）有显著提高（P＜0．01）。血浆IL－2活性测定，治疗后（15．5±3．8）较治疗前（6．3±2．5）有明显提高（P＜0．05）。检测其T4／TS比值，治疗后（1．40±0．31）较治疗前（1．24±0．28）有所提高，但未有显著性差异（P＞0．05）。
Thirty patients with cancer were treated with CD3AK cells/IL-2, including CR+PR in 14 patients, and the effective rate was 46%. According to Ker-nofsky’s standard of quality of life, after treatment (49.66±8.88) was significantly higher than before treatment (37.88±11.84) (P<0.01). Plasma IL-2 activity was significantly higher after treatment (15.5±3.8) than before treatment (6.3±2.5) (P<0.05). The T4/TS ratio was improved after treatment (1.40±0.31) compared with before treatment (1.24±0.28), but there was no significant difference (P>0.05).